Anthropic has launched a new initiative, Claude Science, which appears to be focused on ai drug discovery and is intended to court the pharmaceutical industry. The company's efforts in this area may be part of a larger strategy ahead of a potential ipo. Some pharmaceutical companies, such as BMS, are already working with Anthropic's Claude platform to enhance their research and development capabilities.